Patent & IP news for November 30, 2016

News from Abroad: Not One But Two Decisions Fine Tune the Australian Patent Office's Approach to Life Science Technologies from www.patentdocs.org

By Chris Vindurampulle* -- Two recent Australian Patent Office decisions have provided clarity as to the patentability of isolated nucleic acid sequences following the High Court's decision in D'Arcy v Myriad Genetics1 ('Myriad'). The ...

Share via E–mail | Twitter | Facebook

Never Too Late: If you missed the IPKat last week! from ipkitten.blogspot.com

Been away and want to catch up on last week's IP news? No problem! As always, the IPKat is here to bring you a quick summary -- the 123th edition of Never Too Late.
* Time ...

Share via E–mail | Twitter | Facebook

New Draft Articles For The Protection Of Traditional Knowledge On Table At WIPO from www.ip-watch.org

New draft articles published this morning at the World Intellectual Property Organization committee on traditional knowledge show signs of progress in terms of reducing options. Meanwhile, the United States introduced a proposal for a discussion ...

Share via E–mail | Twitter | Facebook

UK Decision To Ratify EU Patent Court Leaves Key Questions Hanging from www.ip-watch.org

The United Kingdom government is preparing to ratify the Unified Patent Court Agreement, it said on 28 November. The move took the patent community by surprise but failed to relieve uncertainty about what will happen ...

Share via E–mail | Twitter | Facebook

Expert Opinion as to Meaning of Claim Term Excluded as Improper Claim Construction from docketreport.blogspot.com

The court granted in part plaintiff's motion to exclude the testimony of defendants' noninfringement expert because the expert engaged in claim construction. "In his report, [the expert] opines that the term 'support member,' which ...

Share via E–mail | Twitter | Facebook

BREAKING: Antidote found for poisonous priorities from ipkitten.blogspot.com

The Enlarged Board of Appeal at the EPO has issued its order in case G 1/15, but not yet its decision. From the order, it appears that poisonous priorities have been neutralised. The Enlarged ...

Share via E–mail | Twitter | Facebook

(Ir)Rational Choice Theory: Prof. Chris Buccafusco’s Search for the Biases of Creativity from www.iposgoode.ca

What happens when intellectual property law collides with the social sciences? They meld together for some fascinating experiments. In a lecture given at Osgoode Hall Law School earlier this month, Prof. Chris Buccafusco described three ...

Share via E–mail | Twitter | Facebook

Hundreds Of Civil Society Groups Urge RCEP Negotiators To Reject Imported TPP Clauses from www.ip-watch.org

As 16 Asia and Pacific nations prepare to meet in Indonesia next week for the next round of negotiations for a large regional trade agreement called RCEP, more than 300 civil society groups signed a ...

Share via E–mail | Twitter | Facebook

Report: IP, Access To Science A Troubled Relationship from www.ip-watch.org

A new academic report looks into the relationship between intellectual property and access to science and culture, in the wake of work on the issue by former United Nations Special Rapporteur in the field of ...

Share via E–mail | Twitter | Facebook

Patentlyo Bits and Bytes by Anthony McCain from patentlyo.com

Matt Levy: Software Patents Will Survive: How Section 101 Law Is Settling Down Bradley Graveline, Manish Mehta, and Percival Olsen: Proposed “Patent Agent Privilege” Promises Protection For Patent Practitioners and Clients Eric Caligiuri: Federal Circuit ...

Share via E–mail | Twitter | Facebook

Microsoft v. Enfish: Turns Out the Claims Are Obvious from patentlyo.com

This is a discussion of the new Federal Circuit Decision Microsoft v. Enfish appealing a PTAB final decision. In the prior parallel decision – Enfish v. Microsoft, 822 F.3d 1327 (Fed. Cir. 2016), the Federal ...

Share via E–mail | Twitter | Facebook

WHO Board May Discuss UN High-Level Panel Report On Medicines Access from www.ip-watch.org

The UN World Health Organization this week clarified that the possibility exists for the WHO Executive Board to discuss a recently released report from a UN Secretary General-appointed panel that makes recommendations for improving global ...

Share via E–mail | Twitter | Facebook

Pfizer CEO Ian Read Elected To Rotating IFPMA Presidency from www.ip-watch.org

Pfizer Board Chairman and CEO Ian Read has been elected as the next president of the Geneva-based International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), a two-year role.

Share via E–mail | Twitter | Facebook